Skip to main content
Top

Prediction of the early hepatocellular carcinoma development in patients with chronic hepatitis B virus infection using gadoxetic acid-enhanced magnetic resonance imaging

Unlock free access to practice-relevant journal articles

Join our community of medical professionals and register now to access a handpicked selection of journal articles from Springer's Medical portfolio. 

Looking for something specific?

Find articles from over 500 clinical journals from Springer with the search function.

About journals on Springer Medicine

The range of medical journals on Springer Medicine is extremely diverse. It includes the current editions and archives of around 500 English-language journals from almost all medical disciplines published by Springer. 

The specialist literature is usually available both online in full text and as a PDF for download. The online view is optimized in such a way that the specialist texts can be read comfortably on all screen sizes, from desktops to tablets to smartphones. We also include features to support your use of the journals for your research, such as bookmark setting.

Whether you’re interested in internal medicine, surgery, general medicine, gynecology, orthopedics, neurology, or pediatrics, there are excellent journals in almost every subject area, such as the BMC Series, Diabetologia, Breast Cancer Research, Current Obesity Reports, CNS Drugs and many others, all of which are an integral part of the everyday life of doctors across Europe. 

The breadth of content from this suite of journals allows the Springer Medicine team to collect and deliver broad-ranging content across the full spectrum of medical knowledge, with a special focus on topics highlighted by these leading journals and their editorial boards and specialist authors. This guarantees a high quality of content and ensures that our readers are offered the most relevant topics in their respective specialist area. 

Our experienced clinical content managers constantly monitor the needs of medical professionals to provide up-to-date reports from international congresses, expert interviews, and a range of digestible content on emerging topics in the field of medicine.

Published in:

Open Access 01-12-2024 | Hepatocellular Carcinoma | Research

Prediction of the early hepatocellular carcinoma development in patients with chronic hepatitis B virus infection using gadoxetic acid-enhanced magnetic resonance imaging

Authors: Mimi Tang, Danyang Xu, Huilin Jin, Chenyu Song, Xiaoqi Zhou, Huasong Cai, Lujie Li, Meicheng Chen, Yuxin Wu, Yanji Luo, Yuying Chen, Shi-Ting Feng

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Non-hypervascular hypointense nodules (NHHNs) can transform into hypervascular hepatocellular carcinoma (HCC) during the long-term follow-up. However, the risk factors for NHHN hypervascular transformation in chronic hepatitis B virus (HBV)-infected populations are unknown. This study assessed the predictive value of gadoxetic acid-enhanced magnetic resonance imaging (MRI) for HCC development in patients with chronic HBV infection.

Methods

A total of 86 patients with HBV infection who underwent gadoxetic acid-enhanced MRI at the First Affiliated Hospital of Sun Yat-sen University between January 2011 and July 2019 and were followed up for 2 years were retrospectively reviewed. Imaging features, including cirrhosis, steatosis, and NHHNs, were collected. Radiomics features were extracted from the entire liver. The HCC development predictive models were built based on each patient’s clinical data, MRI features, and radiomic features. We then collected the qualitative and quantitative features of each NHHN and investigated the risk factors of hypervascular transformation.

Results

Thirteen patients developed HCC within two years. The risk factors for HCC development in patients with chronic HBV infection included older age, cirrhosis, and NHHNs. The MRI, radiomics, and integrated models developed all had an area under the curve (AUC) above 0.8. The potential risk factors for hypervascular transformation of NHHNs were the diameter of the NHHN (OR = 1.69, 95% CI:1.23, 2.32, P = 0.001) and the signal intensity (SI) ratio of the NHHN to the liver in the hepatobiliary phase (HBP SI ratio*10, OR = 0.36, 95% CI:0.11, 0.85, P = 0.044). The AUC of the hypervascular transformation model was 0.846 (95% CI:0.719, 0.972).

Conclusion

In chronic HBV infection population, patients with older age, cirrhosis and NHHNs are more likely to develop HCC within two years. Models based on these factors or radiomic features can effectively predict HCC development. The diameter of the NHHNs and the signal intensity ratio of NHHN to the liver in the hepatobiliary phase are potential risk factors for the hypervascular transformation of NHHNs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.CrossRefPubMed Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.CrossRefPubMed
3.
go back to reference WHO Guidelines Approved by the Guidelines Review Committee. In: Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. edn. Geneva: World Health Organization Copyright © World Health Organization 2015.; 2015. WHO Guidelines Approved by the Guidelines Review Committee. In: Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. edn. Geneva: World Health Organization Copyright © World Health Organization 2015.; 2015.
4.
go back to reference Huang DQ, Lim SG. Hepatitis B: who to treat? A critical review of international guidelines. Liver Int. 2020;40(Suppl 1):5–14.CrossRefPubMed Huang DQ, Lim SG. Hepatitis B: who to treat? A critical review of international guidelines. Liver Int. 2020;40(Suppl 1):5–14.CrossRefPubMed
5.
go back to reference Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–72.CrossRefPubMed Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–72.CrossRefPubMed
6.
go back to reference Lee HW, Ahn SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol. 2016;22(37):8314–21.CrossRefPubMedPubMedCentral Lee HW, Ahn SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol. 2016;22(37):8314–21.CrossRefPubMedPubMedCentral
7.
go back to reference Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73(6):1368–78.CrossRefPubMed Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73(6):1368–78.CrossRefPubMed
8.
go back to reference Papatheodoridis GV, Voulgaris T, Papatheodoridi M, Kim WR. Risk scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine. Hepatology. 2020;72(6):2197–205.CrossRefPubMed Papatheodoridis GV, Voulgaris T, Papatheodoridi M, Kim WR. Risk scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine. Hepatology. 2020;72(6):2197–205.CrossRefPubMed
9.
go back to reference Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800–6.CrossRefPubMed Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800–6.CrossRefPubMed
10.
go back to reference Narsinh KH, Cui J, Papadatos D, Sirlin CB, Santillan CS. Hepatocarcinogenesis and LI-RADS. Abdom Radiol (New York). 2018;43(1):158–68.CrossRef Narsinh KH, Cui J, Papadatos D, Sirlin CB, Santillan CS. Hepatocarcinogenesis and LI-RADS. Abdom Radiol (New York). 2018;43(1):158–68.CrossRef
11.
go back to reference International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular N. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49(2):658–64.CrossRef International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular N. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49(2):658–64.CrossRef
12.
go back to reference Motosugi U, Bannas P, Sano K, Reeder SB. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma. J Magn Reson Imaging. 2015;41(2):251–65.CrossRefPubMed Motosugi U, Bannas P, Sano K, Reeder SB. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma. J Magn Reson Imaging. 2015;41(2):251–65.CrossRefPubMed
13.
go back to reference Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272(3):635–54.CrossRefPubMed Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272(3):635–54.CrossRefPubMed
14.
go back to reference Kumada T, Toyoda H, Tada T, Sone Y, Fujimori M, Ogawa S, Ishikawa T. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol. 2011;197(1):58–63.CrossRefPubMed Kumada T, Toyoda H, Tada T, Sone Y, Fujimori M, Ogawa S, Ishikawa T. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol. 2011;197(1):58–63.CrossRefPubMed
15.
go back to reference Suh CH, Kim KW, Pyo J, Lee J, Kim SY, Park SH. Hypervascular Transformation of Hypovascular Hypointense Nodules in the Hepatobiliary phase of Gadoxetic Acid-enhanced MRI: a systematic review and Meta-analysis. AJR Am J Roentgenol. 2017;209(4):781–9.CrossRefPubMed Suh CH, Kim KW, Pyo J, Lee J, Kim SY, Park SH. Hypervascular Transformation of Hypovascular Hypointense Nodules in the Hepatobiliary phase of Gadoxetic Acid-enhanced MRI: a systematic review and Meta-analysis. AJR Am J Roentgenol. 2017;209(4):781–9.CrossRefPubMed
16.
go back to reference Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, Tanaka J. Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection. Aliment Pharmacol Ther. 2021;53(12):1309–16.CrossRefPubMed Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, Tanaka J. Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection. Aliment Pharmacol Ther. 2021;53(12):1309–16.CrossRefPubMed
17.
go back to reference Feng ST, Jia Y, Liao B, Huang B, Zhou Q, Li X, Wei K, Chen L, Li B, Wang W, et al. Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI. Eur Radiol. 2019;29(9):4648–59.CrossRefPubMed Feng ST, Jia Y, Liao B, Huang B, Zhou Q, Li X, Wei K, Chen L, Li B, Wang W, et al. Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI. Eur Radiol. 2019;29(9):4648–59.CrossRefPubMed
18.
go back to reference Macari M, Yeretsian R, Babb J. Assessment of low signal adjacent to the falciform ligament on contrast-enhanced MRI. AJR Am J Roentgenol. 2007;189(6):1443–8.CrossRefPubMed Macari M, Yeretsian R, Babb J. Assessment of low signal adjacent to the falciform ligament on contrast-enhanced MRI. AJR Am J Roentgenol. 2007;189(6):1443–8.CrossRefPubMed
19.
go back to reference Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015;21(41):11567–83.CrossRefPubMedPubMedCentral Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015;21(41):11567–83.CrossRefPubMedPubMedCentral
20.
go back to reference Saito K, Moriyasu F, Sugimoto K, Nishio R, Saguchi T, Nagao T, Taira J, Akata S, Tokuuye K. Diagnostic efficacy of gadoxetic acid-enhanced MRI for hepatocellular carcinoma and dysplastic nodule. World J Gastroenterol. 2011;17(30):3503–9.CrossRefPubMedPubMedCentral Saito K, Moriyasu F, Sugimoto K, Nishio R, Saguchi T, Nagao T, Taira J, Akata S, Tokuuye K. Diagnostic efficacy of gadoxetic acid-enhanced MRI for hepatocellular carcinoma and dysplastic nodule. World J Gastroenterol. 2011;17(30):3503–9.CrossRefPubMedPubMedCentral
21.
go back to reference Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology. 2002;225(1):143–9.CrossRefPubMed Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology. 2002;225(1):143–9.CrossRefPubMed
22.
go back to reference Yang H-I, Yuen M-F, Chan HL-Y, Han K-H, Chen P-J, Kim D-Y, Ahn S-H, Chen C-J, Wong VW-S. Seto W-K: risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568–74.CrossRefPubMed Yang H-I, Yuen M-F, Chan HL-Y, Han K-H, Chen P-J, Kim D-Y, Ahn S-H, Chen C-J, Wong VW-S. Seto W-K: risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568–74.CrossRefPubMed
23.
go back to reference El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73. e1261.CrossRefPubMed El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73. e1261.CrossRefPubMed
24.
go back to reference Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, Therneau TM, Kim B, Roberts LR. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2011;9(1):64–70.CrossRef Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, Therneau TM, Kim B, Roberts LR. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2011;9(1):64–70.CrossRef
25.
go back to reference Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B infection: a review. JAMA. 2018;319(17):1802–13.CrossRefPubMed Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B infection: a review. JAMA. 2018;319(17):1802–13.CrossRefPubMed
26.
go back to reference Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2010;8(10):877–83.CrossRef Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2010;8(10):877–83.CrossRef
27.
go back to reference Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2(2):165–73.CrossRefPubMed Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2(2):165–73.CrossRefPubMed
28.
go back to reference Joo I, Kim SY, Kang TW, Kim YK, Park BJ, Lee YJ, Choi JI, Lee CH, Park HS, Lee K, et al. Radiologic-pathologic correlation of Hepatobiliary Phase Hypointense nodules without arterial phase hyperenhancement at Gadoxetic Acid-enhanced MRI: a Multicenter Study. Radiology. 2020;296(2):335–45.CrossRefPubMed Joo I, Kim SY, Kang TW, Kim YK, Park BJ, Lee YJ, Choi JI, Lee CH, Park HS, Lee K, et al. Radiologic-pathologic correlation of Hepatobiliary Phase Hypointense nodules without arterial phase hyperenhancement at Gadoxetic Acid-enhanced MRI: a Multicenter Study. Radiology. 2020;296(2):335–45.CrossRefPubMed
29.
go back to reference Motosugi U. Treat or wait? Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement. Radiology. 2020;296(2):346–7.CrossRefPubMed Motosugi U. Treat or wait? Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement. Radiology. 2020;296(2):346–7.CrossRefPubMed
30.
go back to reference Kobayashi M, Ikeda K, Hosaka T, Sezaki H, Someya T, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer. 2006;106(3):636–47.CrossRefPubMed Kobayashi M, Ikeda K, Hosaka T, Sezaki H, Someya T, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer. 2006;106(3):636–47.CrossRefPubMed
31.
go back to reference Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, et al. JSH Consensus-based clinical practice guidelines for the management of Hepatocellular Carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver cancer. 2014;3(3–4):458–68.CrossRefPubMedPubMedCentral Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, et al. JSH Consensus-based clinical practice guidelines for the management of Hepatocellular Carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver cancer. 2014;3(3–4):458–68.CrossRefPubMedPubMedCentral
32.
go back to reference Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, Kobayashi S, Gabata T, Zen Y, Yamashita T, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol. 2011;21(10):2056–66.CrossRefPubMed Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, Kobayashi S, Gabata T, Zen Y, Yamashita T, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol. 2011;21(10):2056–66.CrossRefPubMed
33.
go back to reference Wang F, Numata K, Chuma M, Nihonmatsu H, Moriya S, Nozaki A, Ogushi K, Fukuda H, Okada M, Ruan L, et al. The value of hepatobiliary phase in EOB-MRI in predicting hypervascularization outcome of non-hypervascular hypointense lesions in high-risk patients for hepatocellular carcinoma. Abdom Radiol (NY). 2021;46(6):2527–39.CrossRefPubMed Wang F, Numata K, Chuma M, Nihonmatsu H, Moriya S, Nozaki A, Ogushi K, Fukuda H, Okada M, Ruan L, et al. The value of hepatobiliary phase in EOB-MRI in predicting hypervascularization outcome of non-hypervascular hypointense lesions in high-risk patients for hepatocellular carcinoma. Abdom Radiol (NY). 2021;46(6):2527–39.CrossRefPubMed
Metadata
Title
Prediction of the early hepatocellular carcinoma development in patients with chronic hepatitis B virus infection using gadoxetic acid-enhanced magnetic resonance imaging
Authors
Mimi Tang
Danyang Xu
Huilin Jin
Chenyu Song
Xiaoqi Zhou
Huasong Cai
Lujie Li
Meicheng Chen
Yuxin Wu
Yanji Luo
Yuying Chen
Shi-Ting Feng
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-13185-7